(Q37842439)

24 August 2017

1 reference

title

Asenapine: a review of its use in the management of mania in adults with bipolar I disorder (English)

1 reference

24 August 2017

2

Lesley J Scott

1 reference

24 August 2017

Claudine M Chwieduk

1

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

251-267

1 reference

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Health and economic burden of metabolic comorbidity among individuals with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine induces differential regional effects on serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Antipsychotic efficacy: relationship to optimal D2-receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine versus olanzapine in acute mania: a double-blind extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Treatment of bipolar disorder: a systematic review of available data and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206700-000000000-00000

Acute and long-term treatment of mania.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21323396

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11206700-000000000-00000

1 reference

Dimensions Publication ID

24 August 2017

1024749831

0 references

1 reference